1. Ca2+-CaM dependent inactivation of RyR2 underlies Ca2+ alternans in intact heart
- Author
-
Jinhong Wei, Blas Echebarria, Darrell D. Belke, John Paul Estillore, Xiaowei Zhong, Leif Hove-Madsen, Bo Sun, Raul Benitez, Wenting Guo, Enrique Alvarez-Lacalle, S.R. Wayne Chen, Alexander Vallmitjana, Ruiwu Wang, Jinjing Yao, Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Fundació La Marató de TV3, Generalitat de Catalunya, Universitat Politècnica de Catalunya. Departament d'Enginyeria de Sistemes, Automàtica i Informàtica Industrial, Universitat Politècnica de Catalunya. Departament de Física, Universitat Politècnica de Catalunya. ANCORA - Anàlisi i control del ritme cardíac, and Universitat Politècnica de Catalunya. BIOCOM-SC - Grup de Biologia Computacional i Sistemes Complexos
- Subjects
calmodulin ,Calmodulin ,Physiology ,Ventricular Tachyarrhythmias ,Sarcoplasmic reticulum ,Numerical modeling ,Electrònica en cardiologia ,heart ,030204 cardiovascular system & hematology ,Ryanodine receptor 2 ,03 medical and health sciences ,0302 clinical medicine ,medicine ,ryanodine ,030304 developmental biology ,0303 health sciences ,biology ,Ryanodine ,Chemistry ,Ryanodine receptor ,Endoplasmic reticulum ,Heart ,medicine.disease ,musculoskeletal system ,Cell biology ,sarcoplasmic reticulum ,Enginyeria biomèdica::Electrònica biomèdica::Electrònica en cardiologia [Àrees temàtiques de la UPC] ,Mutation ,Ventricular fibrillation ,biology.protein ,cardiovascular system ,mutation ,Cardiology and Cardiovascular Medicine - Abstract
Rationale: Ca2+ alternans plays an essential role in cardiac alternans that can lead to ventricular fibrillation, but the mechanism underlying Ca2+ alternans remains undefined. Increasing evidence suggests that Ca2+ alternans results from alternations in the inactivation of cardiac RyR2 (ryanodine receptor 2). However, what inactivates RyR2 and how RyR2 inactivation leads to Ca2+ alternans are unknown. Objective: To determine the role of CaM (calmodulin) on Ca2+ alternans in intact working mouse hearts. Methods and results: We used an in vivo local gene delivery approach to alter CaM function by directly injecting adenoviruses expressing CaM-wild type, a loss-of-function CaM mutation, CaM (1-4), and a gain-of-function mutation, CaM-M37Q, into the anterior wall of the left ventricle of RyR2 wild type or mutant mouse hearts. We monitored Ca2+ transients in ventricular myocytes near the adenovirus-injection sites in Langendorff-perfused intact working hearts using confocal Ca2+ imaging. We found that CaM-wild type and CaM-M37Q promoted Ca2+ alternans and prolonged Ca2+ transient recovery in intact RyR2 wild type and mutant hearts, whereas CaM (1-4) exerted opposite effects. Altered CaM function also affected the recovery from inactivation of the L-type Ca2+ current but had no significant impact on sarcoplasmic reticulum Ca2+ content. Furthermore, we developed a novel numerical myocyte model of Ca2+ alternans that incorporates Ca2+-CaM-dependent regulation of RyR2 and the L-type Ca2+ channel. Remarkably, the new model recapitulates the impact on Ca2+ alternans of altered CaM and RyR2 functions under 9 different experimental conditions. Our simulations reveal that diastolic cytosolic Ca2+ elevation as a result of rapid pacing triggers Ca2+-CaM dependent inactivation of RyR2. The resultant RyR2 inactivation diminishes sarcoplasmic reticulum Ca2+ release, which, in turn, reduces diastolic cytosolic Ca2+, leading to alternations in diastolic cytosolic Ca2+, RyR2 inactivation, and sarcoplasmic reticulum Ca2+ release (ie, Ca2+ alternans). Conclusions: Our results demonstrate that inactivation of RyR2 by Ca2+-CaM is a major determinant of Ca2+ alternans, making Ca2+-CaM dependent regulation of RyR2 an important therapeutic target for cardiac alternans., This work was supported by research grants from the Heart and Stroke Foundation of Canada (G-19-0026444), the Heart and Stroke Foundation Chair in Cardiovascular Research (END611955), the Canadian Institutes of Health Research to S.R.W. Chen (PJT-155940), the Spanish Ministry of Science Innovation and Universities SAF2017-88019-C3-1R, 2R, and 3R (to L. Hove-Madsen, R. Benitez, and B. Echebarria), Marato-TV3 20152030 (to L. Hove-Madsen) and 20151110 (to B. Echebarria), and Generalitat de Catalunya SGR2017-1769 (to L. Hove-Madsen).
- Published
- 2021